The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / BATTER-UP Takes Swing at Potential RA Biomarkers

BATTER-UP Takes Swing at Potential RA Biomarkers

March 10, 2011 • By Sue Pondrom

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In a collaborative effort between the pharmaceutical industry, academia, and community rheumatologists, researchers are evaluating a new biomarker screening test that might help identify patients with rheumatoid arthritis (RA) who are unlikely to benefit from anti-tumor necrosis factor-α (TNFα) medications.

You Might Also Like
  • Letters: Biomarkers for Rheumatoid Arthritis
  • Progress Slow in Development of Useful Biomarkers for Rheumatoid Arthritis Treatment
  • Biomarkers in Rheumatoid Arthritis Remain Elusive
Also By This Author
  • Rheumatoid Arthritis: Time Is of the Essence

Titled the “Biomarkers of Anti-TNF Treatment Efficacy in Rheumatoid Arthritis–Unresponsive Populations (BATTER-UP),” the study is enrolling 1,000 patients with moderate to severe disease who have had an unsatisfactory response to conventional disease-modifying antirheumatic drugs and are about to start treatment with an anti-TNF agent, or who have had an inadequate response to an initial anti-TNF drug and are about to switch to a different one.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“There is a crying need to understand whether there are genetic or other biomarker predictors of TNF response in RA,” says co-lead investigator Peter Gregersen, MD, director of the Center for Genomics and Human Genetics at the North Shore-Long Island Jewish Hospital’s Feinstein Institute for Medical Research in Manhasset, N.Y. “Only 30% of RA patients have a really robust response to TNFs. Close to 30% have no response at all. We don’t have any idea what distinguishes those two groups of people.”

Get Involved

Interested in being a part of BATTER-UP? Contact Crescendo Bioscience at clinicaloperations@crescendobio.com or 855-874-3544 for more information.

The BATTER-UP study will test an eight-gene biomarker set that Dr. Gregersen and colleagues have previously identified as predictive of anti-TNF responsiveness in RA patients.1 The genes are CLTB, MXRA7, CXorf52, COL4A3BP, YIPF6, FAM44A, SFRS2, and PGK1.

“With 1,000 patients, we should find out if Dr. Gregersen’s preliminary data are correct,” says co-lead investigator Michael E. Weinblatt, MD, John R. and Eileen K. Riedman professor of medicine at Brigham and Women’s Hospital in Boston. He added that if “we see something in this study, we want a larger study to validate it before a test can be available for clinical use.” He estimated that the BATTER-UP study, from enrollments to evaluations, will probably last about two years. Further, the study consortium is structured as an academia–industry collaboration with a scientific Advisory board and publication team to ensure rapid dissemination of research.

“It would be great to have a laboratory test that would assist us in making recommendations to patients about treatment approaches in this era of multiple targeted therapies,” Dr. Weinblatt says. “We don’t know yet which treatment will work best for each patient. This is one of the first steps to address this issue.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Conditions, Research Reviews, Rheumatoid Arthritis Tagged With: Biomarker, Clinical research, Rheumatoid arthritis

You Might Also Like:
  • Letters: Biomarkers for Rheumatoid Arthritis
  • Progress Slow in Development of Useful Biomarkers for Rheumatoid Arthritis Treatment
  • Biomarkers in Rheumatoid Arthritis Remain Elusive
  • Biomarkers to Guide Diagnosis, Treatment of Rheumatic Diseases

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.